Pharvaris reported topline Phase 3 data showing its on-demand drug deucrictibant significantly reduced symptom duration versus placebo for hereditary angioedema (HAE) attacks. The result meets the primary endpoint and positions Pharvaris to file for approval and compete with incumbent therapies, including KalVista’s oral agent. Deucrictibant is designed as a rapid-acting on-demand therapy for acute HAE attacks; the Phase 3 topline readout supports the company’s plan to pursue regulatory submissions. The data also sharpen the competitive landscape for oral HAE agents and could prompt near-term commercial and partnering activity. Investors and competitors will be watching full datasets and safety profiles; a successful filing would create an additional on-demand option in a rare-disease market where speed of symptom relief drives clinical and payer value.